Approval · Notice of Compliance 8112 · 2006
CO RISPERIDONE: Notice of Compliance 8112
Issued July 5, 2006
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 8112
- Date
- July 5, 2006
- Company
- Cobalt Pharmaceuticals IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Therapeutic class
- Antipsychotic agent
- Canadian reference product
- RISPERDAL (Janssen-Ortho Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CO RISPERIDONE | 02282585 | Cancelled Post Market |
| CO RISPERIDONE | 02282593 | Cancelled Post Market |
| CO RISPERIDONE | 02282607 | Cancelled Post Market |
| CO RISPERIDONE | 02282615 | Cancelled Post Market |
| CO RISPERIDONE | 02282623 | Cancelled Post Market |
| CO RISPERIDONE | 02282631 | Cancelled Post Market |
Medicinal ingredients
- RISPERIDONE 0.25 MG per TAB
- RISPERIDONE 0.5 MG per TAB
- RISPERIDONE 1 MG per TAB
- RISPERIDONE 2 MG per TAB
- RISPERIDONE 3 MG per TAB
- RISPERIDONE 4 MG per TAB